Clinical Trial Update: Retention Rate of Acalabrutinib in a Non-interventional Setting

View source ↗

Summary

A non-interventional study update evaluating how long patients with chronic lymphocytic leukemia stay on acalabrutinib in real-world use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukaemia (CLL) | Status: ACTIVE_NOT_RECRUITING